Trials / Terminated
TerminatedNCT04611321
Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
A Phase Ib/II, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of IBI318 in Participants With Advanced Cutaneous Squamous Cell Carcinoma.
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of IBI318 (anti-PD-1/PD-L1) in adult participants with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable locally advanced CSCC that is not amenable to surgery and/or radiation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI318 | IBI318 will be given fixed dose via intravenous (IV) infusion on Day 1 of each 14-day cycle until disease progression or loss of clinical benefit. |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2023-03-10
- Completion
- 2023-03-10
- First posted
- 2020-11-02
- Last updated
- 2023-03-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04611321. Inclusion in this directory is not an endorsement.